Eli Lilly and Company $LLY Shares Bought by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 46.7% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 30,753 shares of the company’s stock after acquiring an additional 9,788 shares during the quarter. Liontrust Investment Partners LLP’s holdings in Eli Lilly and Company were worth $28,286,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. raised its stake in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth $356,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Get Eli Lilly and Company alerts:

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Manufacturing expansion supports future demand. Lilly and Resilience are investing $750 million to expand U.S. production of diabetes and obesity medicines. The project is expected to add at least 400 jobs in West Chester, Ohio, and lift Resilience’s Ohio workforce above 1,400. Lilly says the investment is part of approximately $55 billion committed to U.S. manufacturing, helping address supply constraints and support growth. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Retatrutide reaches a late-stage clinical milestone. Lilly completed a Phase 3 trial of retatrutide, its next-generation obesity and diabetes candidate. The completion sets up a potentially important catalyst when results are released, particularly because the drug could expand Lilly’s position in weight management and related cardiovascular markets. Lilly’s Retatrutide Trial Reaches Completion
• Positive Sentiment: Analyst coverage remains broadly favorable, with brokerages assigning a consensus “Moderate Buy” rating. Commentators also point to Lilly’s expanding drug pipeline beyond its current weight-loss products as a longer-term growth driver. Consensus Recommendation of Moderate Buy
• Neutral Sentiment: Lilly’s planned $2.8 billion acquisition of AtaiBeckley would broaden its pipeline into psychedelic-based treatments, but the deal also introduces development and integration risk and is not an immediate earnings catalyst. Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion
• Negative Sentiment: Erste Group Bank reduced its 2026 EPS forecast to $35.34 from $36.33, although the revised estimate remains above the broader consensus of $34.91. The adjustment may be weighing on sentiment while LLY trades at a premium valuation and near its 12-month high. Eli Lilly Analyst Estimate Update

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LLY shares. Guggenheim raised their price target on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,283.64.

Read Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Trading Down 4.5%

LLY opened at $1,155.97 on Friday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.09 trillion, a PE ratio of 41.06, a P/E/G ratio of 1.50 and a beta of 0.51. The firm’s fifty day moving average price is $1,151.01 and its 200 day moving average price is $1,043.41.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the business earned $3.34 EPS. As a group, research analysts expect that Eli Lilly and Company will post 34.91 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Stories

• Five stocks we like better than Eli Lilly and Company
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.